Rheumatoid Arthritis in the UAE

28 October 2008
Study also shows many UAE patients unable to afford the right treatment
Dubai, UAE In a recent study published in a leading American journal, Arthritis and Rheumatism, researchers have identified many gaps in care of Rheumatoid Arthritis (RA) patients in the UAE as compared with Western countries.

In the UAE, only 18% of patients could achieve the goal of 'disease remission' as compared to 36-40% in Western countries including the USA, Netherlands and Finland.

Remission is defined as the absence of clinical signs of inflammation such as red, swollen joints which are warm to the touch; joint pain and stiffness; and loss of joint function.

According to Dr. Scott J. Zashin, author of Arthritis Without Pain-The Miracle Of Anti-TNF Blockers, a very small percentage of patients may be able discontinue their arthritis medications, while over 95% need to continue their medications to remain in remission.

Dr. Zashin explains: "While there is no way to determine who will achieve remission with therapy, patients taking combination therapy are more likely to achieve remission than those taking either drug alone. The longer the disease remains in remission, the less likely it is to become active again."

Patients in the UAE also had more severe disease as compared to other countries, based on disease activity scores.

The study was conducted in collaboration with Finland and USA and covered 5,848 patients in 67 sites over 24 countries, including the UAE as the only Arab country.

The principal investigator for the UAE, Dr. Humeira Badsha, Specialist Rheumatologist at the Dubai Bone and Joint Center, explained that these figures are prevalent because of two- main reasons.

Firstly, patients have a delay in diagnosis of 18 months and a further delay of treatment of 12 months. This is because patients do not think that there is an effective treatment available and there is a general lack of information about the disease.

Secondly, the best chance for 'disease remission' is use of a combination of medications including a new type called biological drugs. Unfortunately, these medications are very expensive and most patients cannot afford them.

"Insurance companies cover this treatment in only 50% of cases. In the USA, 40% of patients with rheumatoid arthritis are receiving these drugs but our data reveals that only 5% of UAE patients are getting them," Dr. Badsha adds.

Dr. Badsha has been the principal investigator in various clinical trials of medications for RA in the UAE. She has further conducted various research studies on Lupus and Autoimmune diseases and published several papers in leading journals.

- Ends -

About Dubai Bone and Joint Center
Dubai Bone and Joint Center (DBAJ) is the first and only center for musculoskeletal treatment and research in the Middle East, offering patients world-class specialists and facilities to improve their quality of life and to have a chance to live a pain free life.

DBAJ aims to operate according to international healthcare standards by offering residents and expatriates in the Middle East the highest quality and the latest innovative treatments and evidence-based medicines according to international protocols.

The center addresses various conditions ranging from children and adult spinal conditions, pelvic and acetabular fractures, reconstructive surgery, and rheumatology. It also offers total joint arthroplasty, revision total joint arthroplasty, limb lengthening and limb deformity correction, infective non-union surgery, foot deformities, neuromuscular disorders, and sports medicine.

DBAJ is a committed associate of the government's efforts to develop Dubai into a 'Center of Medical Excellence' for the region. It is a member of Dubai Healthcare City.